
Medtech Association cheers tariff pause
Key Takeaways
- AdvaMed supports the 90-day tariff pause, offering short-term market stability for the American medtech industry, which is globally leading.
- The association aims to work with the administration to protect the medtech industry's unique role and achieve zero tariffs with key partners.
Association previously expressed grave concerns about the effect of tarrifs.
AdvaMed, the Medtech Association, released a statement supporting today’s announced pause in tariffs.
“We are encouraged by the President’s announcement of a 90-day pause on reciprocal
“Moving forward, we will spend the next 90 days working with the president and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is ‘zero for zero’ tariffs on medtech with all key trading partners.”
The association has previously asked the administration for an
Newsletter
Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.